In the first test of a new law designed to lower drug costs, a New York state panel voted unanimously to seek an additional rebate for a pricey cystic fibrosis drug for the state Medicaid program.
The decision comes in response to concerns that the medicine, which is called Orkambi and has a list price of $272,000, may cause the state Medicaid program to exceed a cap on drug spending. In a 10-to-0 vote, the state Department of Health was authorized to negotiate with Vertex Pharmaceuticals (VRTX) for a rebate that would bring the cost down to about $83,200 and match cost effectiveness estimates.
Last year, New York passed a law last year that permits a drug utilization review panel to consider the need for supplemental rebates. By federal law, state Medicaid programs automatically get a 23.1 percent discount off the list price of a drug. And for every dollar a state spends on Medicaid, the state receives a certain percentage reimbursed by the federal government.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
